Therapy in United Kingdom: Acorda Therapeutics: PharmaVitae Report

• Publication date: May 2012
• Report size: 32 pages

This analysis evaluates the firm ’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the firm ’s historical and projection financial performance. The market research report also gives an in-depth analysis of the firm ’s key prescription pharmaceutical product, and provides a projection sales performance for this drug....

This analysis evaluates the firm ’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the firm ’s historical and projection financial performance. The market research report also gives an in-depth analysis of the firm ’s key prescription pharmaceutical product, and provides a projection sales performance for this drug.Gain insight into Acorda Therapeutics' strategic vision Analyze firm revenue projections by productAcorda obtained rights to its lead product, Ampyra, in 2003. In January 2010, the FDA approved the drug to improve walking in patients with MS. Acorda recorded USD 211m in Ampyra sales in 2011 and it is also being developed to improve walking in patients with cerebral palsy and those with chronic debilitation from a stroke.Compare Acorda Therapeutics' performance against key competitors in the prescription pharmaceutical segment See how, following Zanaflex's patent expiry, Acorda will become increasingly dependent on Ampyra's sales

Therapy Industry in the United Kingdom

ABOUT THIS REPORT•PharmaVitae Explorer database
•Chapter structure - Sales and product analysis
- Financial analysis

•Data sourcing - Analyst consensus

EXECUTIVE SUMMARY•Company introduction - Recent developments
- Corporate relationships

•Strategic overview
•SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats

SALES AND PRODUCT ANALYSIS•Sales overview
•Portfolio overview - Product sales

•Ampyra (dalfampridine) - Ampyra clinical trials in multiple sclerosis
- SWOT analysis
- Portfolio
- Clinical and commercial attractiveness
- Ampyra shows significant effects, but only in a third of patients
- Seizure risk necessitates REMS program
- Ampyra is a useful drug for multiple sclerosis, but payers are likely to restrict uptake due to its high price
- Industry ing of Ampyra has been successful to date

•Zanaflex (tizanidine hydrochloride)
•Diazepam nasal spray (DZNS)
•Early-stage products - GGF-2
- Chondroitinase

FINANCIAL ANALYSIS•Financial performance overview - Operating costs and profit analysis, 2005–11
- Operating costs and profit analysis, 2011–17

APPENDIX•References
•Exchange rates

TABLES•Table: Acorda Research and Development pipeline
•Table: Acorda key catalysts
•Table: Acorda product portfolio overview ($m), 2011–17
•Table: Overview of pivotal trial data for Ampyra, 2011
•Table: Ampyra ongoing trials
•Table: Datamonitor drug assessment summary of Ampyra for multiple sclerosis, 2011
•Table: Acorda operating revenue/cost analysis ($m), 2005–11
•Table: Acorda operating revenue/cost analysis ($m), 2011–17
•Table: Exchange rates, 2011

FIGURES•Figure: PharmaVitae Explorer
•Figure: Acorda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011–17
•Figure: Acorda product sales ($m), 2011–17
•Figure: Ampyra SWOT analysis in multiple sclerosis, 2011
•Figure: Datamonitor drug assessment summary of Ampyra for multiple sclerosis, 2011
•Figure: Acorda operating/cost performance ($m), 2004–16

Companies mentioned

Arriva plc, Hutchison 3G UK Limited, Schindler Holding Ltd., Telindus Group NV